MarketCap
Facebook
X
TelegramQuarterly report 2025-Q2
added 08-05-2025
BioMarin Pharmaceutical Cost of Revenue 2011-2026 | BMRN
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue BioMarin Pharmaceutical
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 580 M | 532 M | 503 M | 471 M | 524 M | 359 M | 315 M | 242 M | 210 M | 152 M | 122 M | 88.4 M | 91.8 M | 84 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 580 M | 84 M | 305 M |
Quarterly Cost of Revenue BioMarin Pharmaceutical
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 150 M | 152 M | - | 188 M | 130 M | 125 M | - | 128 M | 131 M | 135 M | - | 116 M | 123 M | 117 M | - | 104 M | 127 M | 120 M | - | 189 M | 98 M | 111 M | - | 96.9 M | 77.4 M | 89.2 M | - | 78.9 M | 79 M | 82.3 M | - | 59.5 M | 56.3 M | 50 M | - | 50.7 M | 51.6 M | 43.1 M | - | 34.9 M | 38.1 M | 31 M | - | 29.9 M | 31.2 M | 22.8 M | - | 28.1 M | 22.6 M | 20.5 M | - | 24.6 M | 23.6 M | 17.1 M | - | 22.4 M | 19.3 M | 20.8 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 189 M | 17.1 M | 78.3 M |
Cost of Revenue of other stocks in the Biotechnology industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
32.2 M | - | 2.43 % | $ 254 M |  Germany |
 |
Aclaris Therapeutics
ACRS
|
2.79 M | $ 3.01 | 3.79 % | $ 233 M |  USA |
 |
AIkido Pharma
AIKI
|
9 K | - | 1.93 % | $ 17.4 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
369 K | - | -11.43 % | $ 502 K | USA |
 |
Midatech Pharma plc
MTP
|
926 K | - | -18.52 % | $ 27.3 M |  Britain |
 |
Aptorum Group Limited
APM
|
421 K | $ 1.09 | -2.25 % | $ 5.94 M |  China |
 |
Ascendis Pharma A/S
ASND
|
3.52 M | $ 212.41 | 1.48 % | $ 5 B |  Danmark |
 |
BioDelivery Sciences International
BDSI
|
23.4 M | - | -4.8 % | $ 255 M | USA |
 |
BioVie
BIVI
|
312 K | $ 1.14 | 0.49 % | $ 1.68 M | USA |
 |
Acasti Pharma
ACST
|
76 K | - | 4.01 % | $ 150 M |  Canada |
 |
Bellicum Pharmaceuticals
BLCM
|
436 K | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
24.8 M | - | -7.31 % | $ 87 M | USA |
 |
bluebird bio
BLUE
|
33.5 M | - | - | $ 546 M | USA |
 |
Albireo Pharma
ALBO
|
1.36 M | - | -0.23 % | $ 916 M | USA |
 |
BioNTech SE
BNTX
|
2.91 B | $ 94.97 | -0.33 % | $ 27.2 B | Germany |
 |
Amphastar Pharmaceuticals
AMPH
|
358 M | $ 26.71 | -1.07 % | $ 1.29 B | USA |
 |
BeiGene, Ltd.
BGNE
|
70.7 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Anika Therapeutics
ANIK
|
63.6 M | $ 9.6 | 0.52 % | $ 141 M | USA |
 |
Axon Enterprise
AXON
|
841 M | $ 570.58 | -0.27 % | $ 43.2 B | USA |
 |
Catalyst Biosciences
CBIO
|
4.64 M | $ 11.67 | 0.56 % | $ 768 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
602 K | - | - | $ 7.46 M |  Israel |
 |
Aytu BioScience
AYTU
|
20.6 M | $ 2.58 | 1.18 % | $ 16.2 M | USA |
 |
AstraZeneca PLC
AZN
|
12.4 B | $ 92.13 | -0.41 % | $ 96.9 B | Britain |
 |
Acorda Therapeutics
ACOR
|
15.3 M | - | -24.86 % | $ 820 K | USA |
 |
ChromaDex Corporation
CDXC
|
38 M | - | -0.88 % | $ 598 M | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
91.7 M | $ 11.36 | -2.41 % | $ 735 M | USA |
 |
Biogen
BIIB
|
2.31 B | $ 176.12 | -0.16 % | $ 25.6 B | USA |
 |
Certara
CERT
|
155 M | $ 8.78 | -0.9 % | $ 1.41 B | USA |